Tags

Type your tag names separated by a space and hit enter

Patient-rated troubling symptoms of depression instrument results correlate with traditional clinician- and patient-rated measures: a secondary analysis of a randomized, double-blind, placebo-controlled trial.
J Affect Disord 2009; 118(1-3):139-46JA

Abstract

BACKGROUND

The Patient-Rated Troubling Symptoms of Depression (PaRTS-D) instrument assesses the presence and troublesomeness of 8 commonly reported depression-related symptoms from the patient's perspective. A post hoc analysis of a double-blind, randomized risperidone augmentation to antidepressant therapy trial in patients with major depressive disorder explored the relationship between the PaRTS-D instrument and other clinician- and patient-rating scales.

METHODS

Patients completed the PaRTS-D; the Patient Global Improvement Scale (PGIS), Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q), and the Sheehan Disability Scale (SDS), while clinicians completed the Hamilton Rating Scale for Depression (HRSD-17), and the Clinical Global Impressions of Severity (CGI-S) at baseline and at pre-determined study weeks.

RESULTS

In the PaRTS-D instrument, the four most frequently reported and troublesome symptoms were sadness (73.5%, severity 6.8), trouble concentrating (70.9%, 7.3), reduced involvement in pleasurable activities (61.9%, 7.3), and being tense or uptight (56.0%, 6.7). The improvement in PaRTS-D total score was significantly greater in risperidone-augmented compared with placebo-augmented patients at week 4 (p=0.034) and week 6 (p=0.007). Pearson correlations between the PaRTS-D scores and the measures of HRSD-17, CGI-S, PGIS, Q-LES-Q, and SDS were significant at both baseline and at week 6 LOCF (p<0.001 for each comparison).

LIMITATIONS

Results are from a post hoc analysis.

CONCLUSIONS

Significant correlations were observed between the PaRTS-D and other clinician- and patient-rated measures, with PaRTS-D being sensitive to the effects of treatment. These findings suggest that the PaRTS-D instrument is a reliable scale to assess antidepressant activity as experienced by the patients.

Authors+Show Affiliations

Johnson & Johnson Pharmaceutical Research & Development, Titusville, NJ 08560, USA. gpandina@prdus.jnj.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19321206

Citation

Pandina, Gahan J., et al. "Patient-rated Troubling Symptoms of Depression Instrument Results Correlate With Traditional Clinician- and Patient-rated Measures: a Secondary Analysis of a Randomized, Double-blind, Placebo-controlled Trial." Journal of Affective Disorders, vol. 118, no. 1-3, 2009, pp. 139-46.
Pandina GJ, Revicki DA, Kleinman L, et al. Patient-rated troubling symptoms of depression instrument results correlate with traditional clinician- and patient-rated measures: a secondary analysis of a randomized, double-blind, placebo-controlled trial. J Affect Disord. 2009;118(1-3):139-46.
Pandina, G. J., Revicki, D. A., Kleinman, L., Turkoz, I., Wu, J. H., Kujawa, M. J., ... Gharabawi, G. M. (2009). Patient-rated troubling symptoms of depression instrument results correlate with traditional clinician- and patient-rated measures: a secondary analysis of a randomized, double-blind, placebo-controlled trial. Journal of Affective Disorders, 118(1-3), pp. 139-46. doi:10.1016/j.jad.2009.02.019.
Pandina GJ, et al. Patient-rated Troubling Symptoms of Depression Instrument Results Correlate With Traditional Clinician- and Patient-rated Measures: a Secondary Analysis of a Randomized, Double-blind, Placebo-controlled Trial. J Affect Disord. 2009;118(1-3):139-46. PubMed PMID: 19321206.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Patient-rated troubling symptoms of depression instrument results correlate with traditional clinician- and patient-rated measures: a secondary analysis of a randomized, double-blind, placebo-controlled trial. AU - Pandina,Gahan J, AU - Revicki,Dennis A, AU - Kleinman,Leah, AU - Turkoz,Ibrahim, AU - Wu,Jasmanda H, AU - Kujawa,Mary J, AU - Mahmoud,Ramy, AU - Gharabawi,Georges M, Y1 - 2009/03/25/ PY - 2008/08/30/received PY - 2009/02/09/revised PY - 2009/02/19/accepted PY - 2009/3/27/entrez PY - 2009/3/27/pubmed PY - 2009/12/16/medline SP - 139 EP - 46 JF - Journal of affective disorders JO - J Affect Disord VL - 118 IS - 1-3 N2 - BACKGROUND: The Patient-Rated Troubling Symptoms of Depression (PaRTS-D) instrument assesses the presence and troublesomeness of 8 commonly reported depression-related symptoms from the patient's perspective. A post hoc analysis of a double-blind, randomized risperidone augmentation to antidepressant therapy trial in patients with major depressive disorder explored the relationship between the PaRTS-D instrument and other clinician- and patient-rating scales. METHODS: Patients completed the PaRTS-D; the Patient Global Improvement Scale (PGIS), Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q), and the Sheehan Disability Scale (SDS), while clinicians completed the Hamilton Rating Scale for Depression (HRSD-17), and the Clinical Global Impressions of Severity (CGI-S) at baseline and at pre-determined study weeks. RESULTS: In the PaRTS-D instrument, the four most frequently reported and troublesome symptoms were sadness (73.5%, severity 6.8), trouble concentrating (70.9%, 7.3), reduced involvement in pleasurable activities (61.9%, 7.3), and being tense or uptight (56.0%, 6.7). The improvement in PaRTS-D total score was significantly greater in risperidone-augmented compared with placebo-augmented patients at week 4 (p=0.034) and week 6 (p=0.007). Pearson correlations between the PaRTS-D scores and the measures of HRSD-17, CGI-S, PGIS, Q-LES-Q, and SDS were significant at both baseline and at week 6 LOCF (p<0.001 for each comparison). LIMITATIONS: Results are from a post hoc analysis. CONCLUSIONS: Significant correlations were observed between the PaRTS-D and other clinician- and patient-rated measures, with PaRTS-D being sensitive to the effects of treatment. These findings suggest that the PaRTS-D instrument is a reliable scale to assess antidepressant activity as experienced by the patients. SN - 1573-2517 UR - https://www.unboundmedicine.com/medline/citation/19321206/Patient_rated_troubling_symptoms_of_depression_instrument_results_correlate_with_traditional_clinician__and_patient_rated_measures:_a_secondary_analysis_of_a_randomized_double_blind_placebo_controlled_trial_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0165-0327(09)00085-8 DB - PRIME DP - Unbound Medicine ER -